Summary
In 1Q FY03/2027, newly consolidated Kanarabo and clinic-related operations drove revenue to JPY 1,317M (+69.3% YoY). Operating loss was JPY -141M, a JPY +20M improvement YoY. Flagship brand MiiS declined -33.3% YoY due to timing shifts in wholesale deals and deteriorating profitability of e-commerce marketplace promotions. Meanwhile, Kanarabo (Fujiko/b idol) saw post-acquisition PMI gain traction, contributing a fresh JPY 54M in segment profit. Full-year guidance (revenue JPY 6,602M, operating income JPY 50M) was maintained. Under an H2-weighted earnings structure, 1Q progress of 19.9% is in line with the prior two fiscal years.
Key Points (Earnings Takeaways and Growth Actions)
- Corporate Strategy and Market Assessment
- Under Vision 2029, the company targets JPY 1B in operating income next fiscal year and JPY 1.5B thereafter, positioning this as the start of its second growth phase
- Management explicitly acknowledged that domestic beauty/cosmetics market growth has plateaued, making overseas expansion and M&A-driven portfolio broadening unavoidable
- Signaled expansion of M&A targets beyond beauty/cosmetics to brand-related businesses broadly, leveraging core SNS marketing capabilities
- Current Business Progress and Drivers
- MiiS 1Q revenue was JPY 108M (-33.3% YoY), primarily due to timing shifts in large wholesale deals and deteriorating profitability of e-commerce marketplace promotions
- Kanarabo achieved PMI stabilization within six months post-acquisition, delivering JPY 54M in 1Q segment profit as a meaningful earnings contributor
- Matsumura Shoten posted a gross profit margin of 47.3% (vs. 41.8% plan), outperforming on the back of e-commerce revenue growth and AI-driven marketing
- CEO highlighted Fujiko's "Keana Odamari! Cream" as having grown into a staple product on par with the eyebrow tint franchise
- Strategic Initiatives and Inflection Points
- Oripa Shop launched on July 31; sold-out gacha events have already occurred, indicating a solid start. Full-scale contribution expected from 3Q onward
- whomee rebrand Phase 1 launched on August 21, rolling out across all 70 PLAZA stores nationwide and on Qoo10
- MiiS LIFT BRUSH (JPY 39,800 incl. tax) went on general sale August 10, with real demand validated by approximately JPY 14.5M in Makuake crowdfunding support purchases
- Fujiko's "Keana Odamari! Cream" secured placement in approximately 3,000 major drugstore locations (sequential rollout from September)
Outlook and Strategy
- Full-year guidance (revenue JPY 6,602M, operating income JPY 50M) maintained. Against a 1Q operating loss of JPY -141M, the company plans to accumulate JPY +191M from 2Q onward to reach full-year profitability
- The three main profit contributors from 2Q onward are Kanarabo +172, Matsumura Shoten +115, and HaD +108, totaling an expected JPY +395M
- MiiS is pursuing profitability improvement through reallocation of marketplace-specific promotional spend for mm flora* and leveraging TikTok Shop
- M&A strategy is focused on deals that are immediately EPS-accretive post-acquisition, with emphasis on replicating the Matsumura Shoten model of acquiring B2B companies and transforming them into branded businesses
- The company is exploring investments in higher-growth markets beyond beauty/cosmetics, broadly scanning for sectors where SNS marketing capabilities can be leveraged
- UCI (Middle East fund) partnership has been temporarily stalled due to regional geopolitical conditions, but the company plans to expand existing overseas distribution channels—such as Fujiko's 20% China revenue mix—across other brands
Positive Factors
- Kanarabo PMI delivering meaningful contribution with JPY 54M in segment profit; outperforming plan in both e-commerce and wholesale channels, with upside potential in H2 driven by concentration of major marketplace sales events
- Fujiko 1Q revenue of JPY 517M; "Keana Odamari! Cream" sold approximately 30,000 units within two weeks of launch, with an 87.6% repeat purchase rate
- b idol's "Magic Eyebrow Powder" won double awards in the eyebrow category at VoCE and Biteki; post-award sales surged approximately 230%
- Matsumura Shoten's AI-driven marketing and e-commerce transformation is the most advanced within the group, demonstrating the replicability of the M&A value-up model
- Following the launch of bialne's loyalty program, new membership sign-ups increased approximately 2.4x and dormant member reactivations approximately 2.6x
- Oripa Shop generated sold-out gacha events within two weeks of launch, confirming strong affinity with SNS marketing
Concerns and Risks
- MiiS 1Q revenue of JPY 108M (-33.3% YoY); flagship brand struggling, with risk that deteriorating e-commerce marketplace promotional economics could become a structural issue
- Equity ratio has declined for four consecutive fiscal years due to accelerating M&A and net losses (16.5% as of 1Q FY03/2027), potentially constraining financial headroom and limiting future M&A scale
- Goodwill balance of JPY 2,289M (42.9% of total assets), creating impairment risk if acquired companies underperform
- Divestiture of Rice Curry LS resulted in the Other New Business segment declining -46.3% YoY, shrinking the SNS marketing support revenue base
- Consolidated gross margin declined from 53.0% to 50.6%, with increasing mix of lower-margin businesses pressuring profitability
- Overseas expansion plans stalled by Middle Eastern geopolitical situation; no visible concrete progress on UCI partnership
Performance Highlights
Consolidated 1Q FY03/2027 revenue was JPY 1,317M (+69.3% YoY), with an operating loss of JPY -141M (JPY +20M improvement YoY). Newly consolidated Kanarabo (+JPY 645M) and clinic-related operations (+JPY 178M) drove revenue growth, while WinC (JPY -107M) and brand support/holding company (JPY -152M) were drag factors. Adjusted EBITDA was JPY -63M (JPY +50M improvement YoY).
Segment Performance
| Segment | Revenue | YoY | Operating Income | YoY |
|---|---|---|---|---|
| Proprietary Brand | JPY 1,024M | +264.6% | ― | ― |
| Planning & Contract Manufacturing | JPY 117M | -30.6% | ― | ― |
| Other New Business | JPY 176M | -46.3% | ― | ― |
- Fujiko 1Q Revenue: JPY 517M
- MiiS 1Q Revenue: JPY 108M (-33.3% YoY)
- b idol 1Q Revenue: JPY 141M (+JPY 23M QoQ)
- bialne 1Q Revenue: JPY 84M
- bialne Subscription Members: 4,749; retention rate 93.0%
- Fujiko Key Product Repeat Purchase Rate: 87.6%
- Matsumura Shoten Gross Profit Margin: 47.3% (vs. 41.8% plan)
- Adjusted EBITDA: JPY -63M (JPY +50M improvement YoY)
- Adjusted Quarterly Net Income: JPY -61M (JPY +24M improvement YoY)
Q&A List
- Q: UCI made an investment at the beginning of the year, but there appears to be no progress since then. Regarding Middle East-related and overseas expansion—isn't the domestic market alone hitting a ceiling?A: The background to UCI's investment was Middle East expansion, but the war in the Middle East has put various discussions on hold. That said, building overseas revenue is essential, and I recognize that acquiring niche top brands alone will not deliver breakthrough growth. There are two paths forward from here. First, domestically, there are quite a few niche brands and brand-related businesses where SNS marketing can be effective if we broaden our scope. For beauty/cosmetics brands specifically, the Japanese domestic market is essentially at a plateau, so taking them overseas is necessary—but there are domestically growing sectors as well. I cannot comment at this stage on which specific sectors we are targeting or how we plan to expand, but I do not believe the status quo is sufficient, nor is it our policy to focus exclusively on beauty/cosmetics. We will evaluate future M&A toward higher-growth markets. Kanarabo's Fujiko brand already generates 20% of its revenue in China, so it has established overseas distribution channels to some extent—we plan to leverage those channels for other brands to raise our overseas revenue mix. We are not assessing our growth potential solely as an extension of our current portfolio; rather, we intend to leverage our accumulated expertise to invest in higher-growth markets, pursue overseas expansion, and extend into broader brand production domains to achieve breakout growth. Partnership with the Middle Eastern fund remains in our purview.
- Q: Regarding whether the company purchased securities of Club Corp.A: We are unable to comment on that.
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

